← All trials
NCT05317403
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2022
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2027
- First posted
- Apr 7, 2022
- Last posted
- Apr 13, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical College of WisconsinLead sponsor
- Medical College of WisconsinReponsible party - principal investigator
- Medical College of WisconsinStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.